Literature DB >> 15950812

Transcriptional profiling of mesothelioma using microarrays.

Gavin J Gordon1.   

Abstract

Mesothelioma is an asbestos-related neoplasm of the thoracic pleura about which little is known and for which effective therapy is lacking. Large-scale transcriptional profiling using microarrays is frequently a part of studies to explore gene expression patterns in cancer and other diseases. In general, microarray based experiments can facilitate the identification of tumor molecular markers, provide clues relating to mechanisms carcinogenesis, as well as aid in the discovery of candidate targets for therapy. Relatively few studies of this sort have been attempted for mesothelioma, likely due to its relatively rare incidence and by extension the difficulty in acquiring suitable tissues for analysis. Microarray analysis of mesothelioma will likely lead to a better understanding of a highly lethal malignancy and result in the identification of potential therapeutic targets to ultimately affect better treatment options and patient clinical outcome. This mini-review will address general issues pertaining to all expression profiling experiments (e.g., data interpretation) and summarize similar studies that have been attempted for mesothelioma.

Entities:  

Mesh:

Year:  2005        PMID: 15950812     DOI: 10.1016/j.lungcan.2005.03.018

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  12 in total

Review 1.  Cellular and molecular parameters of mesothelioma.

Authors:  Maria E Ramos-Nino; Joseph R Testa; Deborah A Altomare; Harvey I Pass; Michele Carbone; Maurizio Bocchetta; Brooke T Mossman
Journal:  J Cell Biochem       Date:  2006-07-01       Impact factor: 4.429

2.  Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer?

Authors:  Y C Gary Lee
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

3.  Comparative evaluation of set-level techniques in predictive classification of gene expression samples.

Authors:  Matěj Holec; Jiří Kléma; Filip Zelezný; Jakub Tolar
Journal:  BMC Bioinformatics       Date:  2012-06-25       Impact factor: 3.169

4.  Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.

Authors:  Assunta De Rienzo; William G Richards; Beow Y Yeap; Melissa H Coleman; Peter E Sugarbaker; Lucian R Chirieac; Yaoyu E Wang; John Quackenbush; Roderick V Jensen; Raphael Bueno
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

Review 5.  Making the case for molecular staging of malignant pleural mesothelioma.

Authors:  Raphael Bueno
Journal:  Semin Thorac Cardiovasc Surg       Date:  2009

Review 6.  Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.

Authors:  Isabelle Opitz; Raphael Bueno; Eric Lim; Harvey Pass; Ugo Pastorino; Mattia Boeri; Gaetano Rocco
Journal:  Eur J Cardiothorac Surg       Date:  2014-03-12       Impact factor: 4.191

Review 7.  The Molecular Basis of Malignant Pleural Mesothelioma.

Authors:  Benjamin Wadowski; Assunta De Rienzo; Raphael Bueno
Journal:  Thorac Surg Clin       Date:  2020-09-12       Impact factor: 1.750

Review 8.  Discovery of new biomarkers for malignant mesothelioma.

Authors:  Jenette Creaney; Ian M Dick; Bruce W S Robinson
Journal:  Curr Pulmonol Rep       Date:  2015

9.  Novel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functions.

Authors:  Joan M Hevel; Laura C Olson-Buelow; Balasubramanian Ganesan; John R Stevens; Jared P Hardman; Ann E Aust
Journal:  BMC Genomics       Date:  2008-08-07       Impact factor: 3.969

10.  Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).

Authors:  Casey M Wright; Michaela B Kirschner; Yuen Yee Cheng; Kenneth J O'Byrne; Steven G Gray; Karin Schelch; Mir Alireza Hoda; Sonja Klebe; Brian McCaughan; Nico van Zandwijk; Glen Reid
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.